Efficacy of Amlodipine and Olmesartan Medoxomil in Hypertensive Patients With Diabetes and Obesity

Abstract

A subgroup analysis of a prospective, open-label, single-arm titration study in patients with hypertension and type 2 diabetes or obesity is reported. The primary end point was the change from baseline in mean 24-hour ambulatory systolic blood pressure (BP) after 12weeks. Patients received amlodipine 5mg/d and were uptitrated (if seated [Se] BP was ≥120/80mm Hg) at 3-week intervals to amlodipine/olmesartan medoxomil 5/20 mg/d, 5/40 mg/d, and 10/40mg/d. In patients with diabetes and obesity, baseline 24-hour ambulatory BP (±standard deviation) was 145.6±10.4/83.1±9.0mm Hg and 143.7±9.8/84.9±8.2 mm Hg, respectively, and baseline SeBP was 159.1±11.3/90.3±9.2mm Hg and 158.2±12.5/94.2±8.5mm Hg, respectively. Changes from baseline in mean 24-hour ambulatory BP (±standard error of the mean) were -21.5±1.8/-12.6±1.1 mm Hg and 21.6±1.1/13.4±0.8mm Hg in patients with diabetes and obesity, respectively. Prespecified 24-hour ambulatory BP targets of <130/80 mm Hg, <125/75 mm Hg, and <120/80mm Hg were achieved by 79.1%, 53.5%, and 39.5% of patients with diabetes and 75.3%, 58.4%, and 43.8% of obese patients, respectively. The SeBP goal of <130/80mm Hg was achieved by 26.1% of patients with diabetes and <140/90mm Hg was achieved by 78.1% of obese patients. © 2011 Wiley Periodicals, Inc.